MX2023011213A - Métodos y composiciones para tratar la apnea del sueño. - Google Patents

Métodos y composiciones para tratar la apnea del sueño.

Info

Publication number
MX2023011213A
MX2023011213A MX2023011213A MX2023011213A MX2023011213A MX 2023011213 A MX2023011213 A MX 2023011213A MX 2023011213 A MX2023011213 A MX 2023011213A MX 2023011213 A MX2023011213 A MX 2023011213A MX 2023011213 A MX2023011213 A MX 2023011213A
Authority
MX
Mexico
Prior art keywords
methods
sleep apnea
compositions
treating sleep
antagonist
Prior art date
Application number
MX2023011213A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence G Miller
Ronald Farkas
Luigi Taranto-Montemurro
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of MX2023011213A publication Critical patent/MX2023011213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023011213A 2021-03-24 2022-03-23 Métodos y composiciones para tratar la apnea del sueño. MX2023011213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163165342P 2021-03-24 2021-03-24
PCT/US2022/021462 WO2022204228A1 (en) 2021-03-24 2022-03-23 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
MX2023011213A true MX2023011213A (es) 2023-10-02

Family

ID=81388916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011213A MX2023011213A (es) 2021-03-24 2022-03-23 Métodos y composiciones para tratar la apnea del sueño.

Country Status (15)

Country Link
US (1) US20240173337A1 (https=)
EP (1) EP4313153A1 (https=)
JP (1) JP2024511091A (https=)
KR (1) KR20230159462A (https=)
CN (1) CN117062626A (https=)
AU (1) AU2022245235A1 (https=)
BR (1) BR112023019256A2 (https=)
CA (1) CA3212035A1 (https=)
CL (1) CL2023002824A1 (https=)
CO (1) CO2023012587A2 (https=)
CR (1) CR20230457A (https=)
GE (1) GEAP202416361A (https=)
IL (1) IL307186A (https=)
MX (1) MX2023011213A (https=)
WO (1) WO2022204228A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746126B1 (en) * 2018-01-30 2024-07-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea or simple snoring
EP4635514A3 (en) * 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea
JP2023520455A (ja) * 2020-04-02 2023-05-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法および組成物

Also Published As

Publication number Publication date
BR112023019256A2 (pt) 2023-10-17
CA3212035A1 (en) 2022-09-29
WO2022204228A1 (en) 2022-09-29
KR20230159462A (ko) 2023-11-21
JP2024511091A (ja) 2024-03-12
CR20230457A (es) 2024-02-19
CN117062626A (zh) 2023-11-14
CO2023012587A2 (es) 2023-10-19
AU2022245235A1 (en) 2023-10-12
EP4313153A1 (en) 2024-02-07
GEAP202416361A (en) 2024-04-25
US20240173337A1 (en) 2024-05-30
CL2023002824A1 (es) 2024-01-26
IL307186A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
GEAP202316320A (en) Methods and compositions for treating sleep apnea
MX2024001713A (es) Metodos y composiciones para tratar la apnea del sue?o.
PH12021550616A1 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
MX382765B (es) Tratamiento para la colangitis biliar primaria.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MX2023011213A (es) Métodos y composiciones para tratar la apnea del sueño.
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
AU2018333954A1 (en) Methods and compositions to inhibit dependence on opioids
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
MX2023008573A (es) Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
MX2023014709A (es) Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o.
TN2014000269A1 (en) Novel therapeutic use of p75 receptor antagonists
AU2018333952A1 (en) Methods and compositions to inhibit symptoms associated with opioid withdrawal
EA032957B1 (ru) Комбинация обратных агонистов гистамин-3 рецептора с ингибиторами ацетилхолинэстеразы
EA201990481A1 (ru) Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda
MX2010007967A (es) N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.
EA201992569A1 (ru) Способы и композиции для лечения апноэ во сне